Dec 27, 2023 / 01:30PM GMT
Operator
Good morning and welcome, ladies and gentlemen, to the Cytokinetics conference call announcing the top line results of SEQUOIA-HCM. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen only mode company's request.
We will open the call for question and answers after the presentation. We will allow hoover up to one question per person. I would now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications, Investor Relations, please.
Diane Weiser - Cytokinetics Inc - IR Contact
Welcome everyone, and thanks for joining us on our call today, which will focus on the top line results of SEQUOIA-HCM, the pivotal Phase three clinical trial of Affy Camden, our next-in-class cardiac myosin inhibitor. Robert Blum, our President and Chief Executive Officer, will begin with an overview of today's announcement. Then Fady Malik, our Executive Vice President of R&D, will present the top-line results. Robert will then provide closing remarks before we open
Cytokinetics Inc to Discuss the Topline Results from SEQUOIA-HCM Transcript
Dec 27, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers